Noscendo will test clinical value for cell-free DNA metagenomic sequencing in sepsis diagnosis through a new €7.5 million German trial. The OptiSep project will position Noscendo’s CE-IVDR-marked Disqver platform as a primary technology partner, aiming to demonstrate clinical actionability and cost benefit. The initiative is funded via the innovation committee of Germany’s Federal Joint Committee (G-BA) and will involve multiple intensive care and emergency medicine stakeholders, including DIVI and Leipzig University Hospital. Project management is led by Alexandra Ramshorn-Zimmer. OptiSep builds on the earlier DigiSep study, which evaluated Disqver in parallel with standard care and blood culture in a randomized interventional design across 24 hospitals, with 410 patients enrolled. The key watchpoint for the field will be whether sequencing results can reliably change treatment decisions early enough to reduce time-to-appropriate therapy while remaining economically viable for routine care pathways.